Emerging treatments for bipolar disorder: Safety and adverse effect profiles

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 276-285

  Marken, Patricia A ^a,b   Pies, Ronald W ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Bipolar disorder treatment; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LIPID; MOOD STABILIZER; NEW DRUG; OLANZAPINE; OXCARBAZEPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZONISAMIDE;

AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; APPETITE DISORDER; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BIPOLAR DISORDER; BLURRED VISION; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTRIGLYCERIDEMIA; HYPOMANIA; HYPONATREMIA; KETOACIDOSIS; LIPID BLOOD LEVEL; LIVER TOXICITY; MALAISE; MANIA; MEDLINE; MENSTRUAL IRREGULARITY; METABOLIC ACIDOSIS; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES; TREATMENT OUTCOME; TREMOR; URINE INCONTINENCE; URINE RETENTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; HUMANS; MEDLINE; SAFETY;

EID: 33144472671     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G112     Document Type: Review

References (114)

1. Diagnostic and statistical manual of mental disorders. Text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000.
2. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11.
3. Hirschfeld RMA, Bowden CL, Perlis RH, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 suppl):1-50.
4. Keck PE Jr, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The Expert Consensus Guideline Series: treatment of bipolar disorder 2004. Postgrad Med Special Rep 2004.
5. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63:288-99.
6. Physicians' desk reference. 59th ed. Montvale, NJ: Thomson PDR, 2005.
7. Pies RW. Handbook of essential psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Association, 2005.
8. Lieberman JA. Aripiprazole. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:487-94.
9. Marder SR, Wirshing DA. Clozapine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:443-56.
10. Schulz SC, Olson S, Kotlyar M. Olanzapine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:457-72.
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72.
12. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-7.
13. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-35.
14. Nasrallah HA. Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr 2003;8(11 suppl 2):23-5.
15. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
16. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
17. Package insert. Geodon (ziprasidone HCl) capsules, Geodon (ziprasidone mesylate) for injection. New York: Pfizer Roering, May 2005.
18. Laughren T, Gordon M. FDA background on Zeldoxä (ziprasidone hydrochloride capsules). Pfizer, Inc. Bethesda, MD: Psychopharmacological Drugs Advisory Committee, July 19, 2000.
19. Su KP, Chang HC, Shen WW. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002;159:1062-3.
20. Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004;65:1537-45.
21. Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tonen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Disord 2003;73:147-53.
22. Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277-84.
23. Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 2000;15:499-512.
24. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
25. Reinares M, Martinez-Aran A, Colom F, Benabarre A, Salamero M, Vieta E. [Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients] Spanish. Actas Esp Psiquiatr 2000;28:231-8.
26. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002;73:297-311.
27. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9.
28. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.
29. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003;5(suppl 2):20-35.
30. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-81.
31. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.
32. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
33. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-9.
34. Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004;65:1679-87.
35. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-70.
36. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
37. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003;170:157-66.
38. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-35.
39. Torrey EF, Swalwell CI. Fatal olanzapine-induced ketoacidosis (letter). Am J Psychiatry 2003;160:2241-4.
40. Goff DC. Risperidone. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:495-505.
41. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-54.
42. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25.
43. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-42.
44. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-43.
45. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-44.
46. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003;160:1618-20.
47. Bahk WM, Yoon BH, Lee KU, Chae JH. Combination of mood stabilizers with quetiapine for treatment of acute bipolar disorder: an open label study. Hum Psychopharmacol 2004;19:181-5.
48. Suppes T, McElroy SL, Keck PE, et al. Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int Clin Psychopharmacol 2004;19:173-4.
49. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65 (suppl 6):30-44.
50. Altamura AC, Salvadori D, Madaro D, Santini A, Mundo E. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76:267-71.
51. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-54.
52. Lieberman JA. Quetiapine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:473-86.
53. Package insert. Seroquel (quetiapine fumate). Wilmington, DE: AstraZeneca, June 2005.
54. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-8.
55. Keck PE Jr, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother 2001;2:1033-42.
56. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001;21:717-30.
57. Goodnick PJ. Ziprasidone: profile on safety. Expert Opin Pharmacother 2001;2:1655-62.
58. Brieger P. Hypomanic episodes after receiving Ziprasidone: an unintended "on-off-on" course of treatment. J Clin Psychiatry 2004;65:132-5.
59. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull 2001;35:66-79.
60. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-81.
61. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
62. Cohen ST, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole co-prescription. J Clin Psychiatry 2005;66:135-6.
63. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
64. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-64.
65. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-7.
66. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41.
67. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994;44:2247-9.
68. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-90.
69. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-8.
70. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16:63-73.
71. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48.
72. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.
73. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-73.
74. Janicak PG, Davis JM, Preskhorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
75. Lenox RH, Manji HK. Lithium. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 1st ed. Washington, DC: American Psychiatric Association, 1995:303-49.
76. Maxmen JS. Antidepressants. Psychotropic drugs: fast facts. 1st ed. New York: WW Norton & Company, 1991:57-97.
77. Shelton MD, Calabrese JR. Lamotrigine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 2003:615-26.
78. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004;65:204-10.
79. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-84.
80. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003;64(suppl 8):22-9.
81. Khan A, Ginsberg LD, Asnis GM, et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry 2004;65:1483-90.
82. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-9.
83. Fervenza FC, Kanakiriya S, Kunau RT, Gibney R, Lager DJ. Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. Am J Kidney Dis 2000;36:1034-40.
84. Wang PW, Ketter TA, Becker OV, Nowakowska C. New anticonvulsant medication uses in bipolar disorder. CNS Spectr 2003;8:930-7.
85. Labiner DM. Lamotrigine and rash: scratching beneath the surface. J Clin Psychiatry 2002;63:1010-1.
86. Ketter TA, Wang PW, Chandler RA, et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry 2005;66:642-5.
87. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000;55:588-91.
88. Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000;43(5 pt 2):898-9.
89. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002;72(suppl 1):S23-34.
90. Hummel B, Waiden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002;4:412-7.
91. Kramer G. Oxcarbazepine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:479-84.
92. Rabasseda X. Oxcarbazepine: anticonvulsant profile and safety. Drugs Today (Bare) 2001;37:333-55.
93. Package insert. Trileptal (oxycarbazepine). Cambridge, MA: Novartis, March 2005.
94. Vieta E, Torrent C, Garcia-Ribas G, et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002;22:431-5.
95. Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Adjunctive topiramate in bipolar II disorder. World J Biol Psychiatry 2003;4:172-6.
96. Bahk WM, Shin YC, Woo JM, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:115-21.
97. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001;3:215-32.
98. Berk M, Berk L. Mood stabilizers and treatment adherence in bipolar disorder addressing adverse events. Ann Clin Psychiatry 2003;15:217-24.
99. Prescribing information. Topamax (topiramate). Raritan, NJ: Ortho-McNeil Pharmaceutical, January 2004.
100. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 pt 2):249-55.
101. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
102. Erfurth A, Kammerer C, Grunze H, Normann C, Walden J. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res 1998;32:261-4.
103. Ramsay RE. Gabapentin: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:354-60.
104. Young LT, Robb JC, Hasey GM, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999;55:73-7.
105. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:394-6.
106. Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003;64:781-4.
107. Post RM, Altshuler LL, Frye MA, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005;66:370-4.
108. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepilepuc drug. Epilepsy Res 2001;47:77-90.
109. Leppik E, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73.
110. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
111. Pies R. Combining lithium and anticonvulsants in bipolar disorder: a review. Ann Clin Psychiatry 2002;14:223-32.
112. Gelenberg AJ, Pies R. Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry 2003;15:203-6.
113. Ghaemi SN, Ko JY. Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in psychiatry. New York: Marcel Dekker, 2002:35-77.
114. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60(suppl 21):16-9.